All Posts By

Luciana Nofal

Skin of Color STD Ted Rosen

Sexually Transmitted Diseases in Skin of Color: Crisis State

By Skin of Color Update Agenda

As one would expect, Dr. Ted Rosen’s session at the Skin of Color Seminar Series 2018 (now Skin of Color Update) on Sexually Transmitted Diseases (STDs) in Skin of Color was engaging, informative, and shocking to many in the audience. Dr. Rosen addressed the increasing rates of STDs in the United States and highlighted the alarming predominance in non-white ethnic groups.

*Clinical pearls* from this session are bolded, underlined, and marked with asterisks.

The STD data from 2017 is worse than 2016, which was worse than 2015, and so on. *Every year, 20×106new STDs are diagnosed!*Over 50% of Americans will contract an STD during their lifetime, often before the age of 25. Teenagers are at high risk as well, with 1 in 4 teenagers developing an STD. First piece of good news: *Sex in high school is decreasing*in the US, with the exception of a few states(from east to west): North Carolina, Michigan, North Dakota, Wyoming, and Arizona. Perhaps this will correlate with decreased STD transmission among teenagers in the coming years.

Read more.

Excerpt provided with permission. Originally published by Next Steps in Dermatology. All rights reserved.

 

 

The Use of Deoxycholic Acid for the Clinical Reduction of Excess Submental Fat in Indian Patients

By SOC Manuscripts

Source: J Drugs Dermatol. 2019;18(3):266-272.

Debraj Shome MD FRCS, FACS, MBA Stuti Khare MD, Rinky Kapoor MD

The injectable adipocytolytic drug deoxycholic acid (DCA) is the first pharmacological intervention approved for the reduction of submental fat (SMF) and offers an alternative to invasive measures to improve the submental profile and the cervico-mental angle. DCA injection (ATX-101, Kybella [United States], Belkyra [Canada]; Kythera Biopharmaceuticals, Inc., Westlake Village, CA, acquired by Allergan, Inc.), are proprietary formulations of synthetically derived DCA that is FDA approved for improvement in the appearance of moderate to severe convexity or fullness associated with SMF.

Aim: As none of the aforementioned are available in India, we undertook this study to study the efficacy of generic DCA for SMF reduction in Indian patients.

Read more.

Latino JDD Rendon

Dermatological Concerns in the Latino Population

By SOC Manuscripts

Source: J Drugs Dermatol. 2019;18(3 Suppl):s112-114. 

Marta I. Rendon MD 

The Journal of Drugs in Dermatology (JDD) published a supplement on the dermatological concerns in the Latino population authored by Marta I. Rendon, MD.

The Latino, or Hispanics in the United States, are the drivers behind demographic growth. They are heterogeneous in many dimensions related to health risks and dermatological conditions. Understanding the heterogeneity and clinical manifestation of skin concerns in such population is essential for health care providers. At the annual meeting of the American Academy of Dermatology in 2018, Dr. Rendon chaired a special symposium titled “Skin Issues in Latino Patients”, with the objective of training clinical practitioners how to better provide care and education to our diverse patients.

Click “Download Original Article” here

  • Introduction: Dermatological Concerns in the Latino Population Marta I. Rendon MD
  • Hyperpigmentation Disorders in Hispanic Population in the United States Marta I. Rendon MD
  • Disorders of Hypopigmentation Yemisi Dina BS, Jacqueline McKesey MD MS, Amit G. Pandya MD
  • Skin Cancer in Hispanics in the United States Maritza I. Perez MD
  • Photoaging and Photoprotection in United States Hispanic Population Qian Zheng MD PhD, Janet Wangari-Talbot PhD, Charbel Bouez PhD, and Michele Verschoore MD
  • Acne and Rosacea: Special Considerations in the Treatment of Patients With Latin American Ancestry Mercedes Florez-White MD
  • Cosmetic Laser Procedures in Latin Skin Sheila Jalalat MD, Eduardo Weiss MD
Skin of Color Update CCCA

Pearls from Primary Cicatricial Alopecias in Black Women

By Sessions, Skin of Color Update Agenda

Hair Apparent: A Multi-Part Series on Hair Disorders – Part II

Dermatology residents from throughout the Washington DC area recently convened at a recent hair disorders symposium, where distinguished experts in the field of hair disorders discussed the evaluation, work-up, and treatment of a wide variety of alopecias and scalp disorders. A treasure trove of clinical pearls was shared along the way, and the attendees learned a host of new strategies to apply to the management of hair loss, which is both widely prevalent and frequently undertreated. Attend Skin of Color Update in to learn more or continuing reading below.

This post is the second of a multi-part series that summarizes salient points from each of the lectures, as well as strategies that residents can add to their alopecia armamentarium.

 

Read more.

Seborrheic Dermatitis in Skin of Color: Clinical Considerations

By SOC Manuscripts

Source: J Drugs Dermatol. 2019;18(1):24-27.

May Elgash BS, Ncoza Dlova MBChB FCDerm PhD, Temitayo Ogunleye MD, Susan C. Taylor MD

Skin of Color Update 2019 faculty Susan C. Taylor, MD and colleagues published a paper in the January 2019 issue of the Journal of Drugs in Dermatology on seborrheic dermatitis in skin of color.  Read the abstract below or login in to JDD for the full manuscript.

Abstract: Seborrheic dermatitis is a common, relapsing, inflammatory skin condition of unclear etiology. The Malassezia yeast genus are believed to play a role. Seborrheic dermatitis commonly affects areas of the skin with high sebum production, including the scalp, nasolabial folds, glabella, eyebrows, beard, ears, retroauricular skin, sternum, and other skin folds. Seborrheic dermatitis may present differently in individuals with skin of color. Darker-skinned individuals may present with scaly, hypopigmented macules and patches in typical areas of involvement. Arcuate or petal-like patches may be seen, specifically termed petaloid seborrheic dermatitis. Children of color often do not experience the classic “cradle cap” appearance of seborrheic dermatitis, and have erythema, flaking, and hypopigmentation of the affected areas and folds of skin. Seborrheic dermatitis tends to respond well to conventional treatments, although it tends to recur. Skin of color patients may require a modified treatment approach which takes into account differences in hair texture and hair washing frequency. This paper aims to highlight these differences to help reduce disparities in the management of seborrheic dermatitis in patients of color. To read the full manuscript with your JDD subscription, click here.

Seborrheic Dermatitis in Skin of Color

Seborrheic Dermatitis in Skin of Color: Clinical Considerations

By SOC Manuscripts

Seborrheic dermatitis is a common, relapsing, inflammatory skin condition of unclear etiology. The Malassezia yeast genus are believed to play a role. Seborrheic dermatitis commonly affects areas of the skin with high sebum production, including the scalp, nasolabial folds, glabella, eyebrows, beard, ears, retroauricular skin, sternum, and other skin folds. Seborrheic dermatitis may present differently in individuals with skin of color. Darker-skinned individuals may present with scaly, hypopigmented macules and patches in typical areas of involvement. Arcuate or petal-like patches may be seen, specifically termed petaloid seborrheic dermatitis. Children of color often do not experience the classic “cradle cap” appearance of seborrheic dermatitis, and have erythema, flaking, and hypopigmentation of the affected areas and folds of skin. Seborrheic dermatitis tends to respond well to conventional treatments, although it tends to recur. Skin of color patients may require a modified treatment approach which takes into account differences in hair texture and hair washing frequency. This paper aims to highlight these differences to help reduce disparities in the management of seborrheic dermatitis in patients of color. J Drugs Dermatol. 2019;18(1):24-27.

 

Read the full article on JDDonline.com.

Hair disorders skin of color update

Clinical Approach to Hair Loss in Pediatric Patients

By Skin of Color Update Agenda

Physicians from throughout the Washington DC area recently convened at a hair disorders symposium, where distinguished experts in the field of hair disorders discussed the evaluation, work-up, and treatment of a wide variety of alopecias and scalp disorders. A treasure trove of clinical pearls was shared along the way, and the attendees learned a host of new strategies to apply to the management of hair loss, which is both widely prevalent and frequently undertreated.

This is an excerpt from a multi-part series on Next Steps in Dermatology that summarizes salient points from each of the lectures, as well as strategies that physicians can add to their alopecia armamentarium.

This post is devoted to Dr. Leslie Castelo-Soccio’s lecture, “Clinical approach to hair loss in pediatric patients.” Dr. Castelo-Soccio is a pediatric dermatologist as well as the Dermatology Section’s Director of Clinical Research at Children’s Hospital of Philadelphia. She is an expert in alopecia as well as genetic skin disease. Her lecture provided an incredibly useful roadmap for residents learning to navigate the following aspects of caring for the pediatric alopecia patient…

Read more.

Clinical Evaluation of Safety and Efficacy of Fractional Radiofrequency Facial Treatment of Skin Type VI Patients

By SOC Manuscripts

Source: J Drugs Dermatol. 2018;17(11):1169-1172.

Eliot F. Battle Jr. MD and Sally Battle CNMT

We are excited to highlight a November 2018 published in the Journal of Drugs in Dermatology by our very own co-founder, Eliot F. Battle, MD.   The study was intended to evaluate the safety and efficacy of fractional RF technology for the treatment of patients with Fitzpatrick skin type VI. We recommend you read the abstract or login with your JDD subscription for the full manuscript here.

Innovations in Skin of Color Dermatology Award Goes to Eliot Battle, MD

By Media Coverage

Source: DermWire

Eliot Battle, MD has been awarded the Innovations in Skin of Color Dermatology Award. The award was presented by  The Journal of Drugs in Dermatology (JDD) at the Skin of Color Seminar Series (SOCSS) held May 5 and 6, 2018, in New York. The award recognizes individuals who have fostered innovation and improvement in dermatology through increased emphasis on skin of color education and research. Dr. Battle is a co-founder and co-chair of SOCSS.

“Dr. Battle’s tireless support and advocacy has been instrumental in starting the industry wide shift towards dermatology education that is inclusive of all skin types,” said Shelley Tanner, CEO and president of SanovaWorks, which produces the JDD and SOCSS. ”Dr. Battle received the award for his commitment to safe, accessible, and cutting-edge dermatology care for patients of all ethnicities and for being a champion for this cause.”

Read more. 

Epidemiology of Skin Diseases in a Diverse Patient Population

By SOC Manuscripts

Source: J Drugs Dermatol. 2018;17(10):1032-1036

Jewell V. Gaulding MD, Daniel Gutierrez MD, Bhavnit K. Bhatia MD, Xiaoxia Han PhD, Richard Krajenta BS, Christine Neslund-Dudas PhD, Henry W. Lim MD, Ellen N. Pritchett MD MPH

Abstract
BACKGROUND: Epidemiologic studies of patients who present to dermatology clinics are necessary to identify the needs of patients. OBJECTIVE: To quantify and compare diagnoses according to race, ethnicity, and socioeconomic status (SES) at 6 general dermatology clinics from January 2013 to December 2016. METHODS: A retrospective cohort of new patients was established using an electronic medical record database. Primary diagnoses and diagnostic codes were recorded. Geocoding was utilized to obtain SES. RESULTS: There were 65969 new patient visits. Racial and ethnic demographics were obtained with the overall top 3 conditions being eczema or dermatitis, benign skin neoplasm, and adnexal disease. In blacks, however, follicular disorders were the third most common condition seen. The most frequently encountered diagnoses at the clinics with the highest and lowest SES were benign skin neoplasm and eczema or dermatitis, respectively.

Read more.